Arcutis Biotherapeutics, Inc. (ARQT) Q2 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Ladies and gentlemen, thank you for standing by. Welcome to Arcutis Biotherapeutics, Inc. Second Quarter twenty twenty six Earnings Conference Call. At this time, participants are in a listen only mode. After the speakers' presentation, there will be a question and answer session. And to ask a question during this session, you would need to press 11 on your telephone. You will then hear an automated message advising your hand is raised. Please be advised that today's conference is being recorded. I would like now to turn the conference over to Brian Shulkopf, Head of Investor Relations. Please go ahead. Thank you, Michelle. Good afternoon, everyone, and thank you for joining us today to review our second quarter twenty twenty six financial results and business update. Slides for today's call are available on the Investors section of the Arcutis website. Joining me on the call today are Frank Watanabe, President and CEO of Arcutis Patrick Burnett, Chief Medical Officer and Lata Vairavyan, Chief Financial Officer. I would like to remind everyone that we will be making forward looking statements during this call. These statements are subject to certain risks and uncertainties, and our actual results may differ. We encourage you to review all the company's filings with the Securities and Exchange Commission, including descriptions of our business and risk factors. With that, let me hand it over to Frank to begin today's call. Thanks, Brian, and good afternoon, everyone. As always, we appreciate you guys making the time to join us on our quarterly update call. I'm going to start this afternoon with a review of our very productive second quarter, as we continue to deliver meaningful innovation for patients with chronic inflammatory skin diseases, and continue to execute ag...